Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals has reported Total Current Liabilities for 10 years, with the latest figure at $71.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 24.04% year-over-year to $71.1 million; the trailing twelve-month figure through Mar 2026 stood at $71.1 million (up 24.04% YoY), and the FY2025 full-year result was $85.1 million, up 42.54% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $71.1 million, down from $85.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $85.1 million in Q4 2025, with the low at $20.3 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $48.1 million, with a median of $51.8 million recorded in 2024.
• Year-over-year, Total Current Liabilities surged 119.1% in 2022 and grew 10.71% in 2025.
• Tracing CRNX's Total Current Liabilities over 5 years: stood at $27.7 million in 2022, then surged by 58.5% to $43.9 million in 2023, then jumped by 35.82% to $59.7 million in 2024, then surged by 42.54% to $85.1 million in 2025, then slipped by 16.44% to $71.1 million in 2026.
• The last three Total Current Liabilities figures came in at $71.1 million (Q1 2026), $85.1 million (Q4 2025), and $74.2 million (Q3 2025), per Business Quant data.

Peer Comparison